Abstract
Using chlorotetracycline (CTC) as a probe we studied calcium homeostasis of platelets in various disorders. Studied were healthy subjects and patients with disorders where platelets play an important role. These included thromboses, hypertension, diabetes mellitus, vasculitis, immune thrombocytopenia, thrombotic thrombocytopenic purpura, myelofibrosis, hemolytic anemias and uremia. Significant elevation of calcium levels were observed in all of these disorders except uremia. Nifedipine reduced or normalized the increased levels in most patients and its discontinuation resulted in a return of the abnormality. We propose that platelets in thromboses and related disorders are exposed to subcritical concentrations of activating factors, leading to enhanced calcium influx and elevated free cytoplasmic calcium followed by elevated resting dense tubular calcium. Nifedipine appears to protect platelets from these stimuli and coupled with their known action on vessel walls, calcium channel blockers show promise as antiatherogenic as well as antithrombotic agents.
| Original language | English |
|---|---|
| Pages (from-to) | 135-143 |
| Number of pages | 9 |
| Journal | Thrombosis Research |
| Volume | 45 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jan 15 1987 |
Fingerprint
Keywords
- artherosclerosis
- CTC probe
- platelet
- platelet calcium
- thromboses
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Hematology
Cite this
Increased platelet calcium in thrombosis and related disorders and its correction by nifedipine. / Ahn, Yeon; Jy, Wenche; Harrington, W. J.; Shanbaky, N.; Fernandez, L. F.; Haynes, D. H.
In: Thrombosis Research, Vol. 45, No. 2, 15.01.1987, p. 135-143.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Increased platelet calcium in thrombosis and related disorders and its correction by nifedipine
AU - Ahn, Yeon
AU - Jy, Wenche
AU - Harrington, W. J.
AU - Shanbaky, N.
AU - Fernandez, L. F.
AU - Haynes, D. H.
PY - 1987/1/15
Y1 - 1987/1/15
N2 - Using chlorotetracycline (CTC) as a probe we studied calcium homeostasis of platelets in various disorders. Studied were healthy subjects and patients with disorders where platelets play an important role. These included thromboses, hypertension, diabetes mellitus, vasculitis, immune thrombocytopenia, thrombotic thrombocytopenic purpura, myelofibrosis, hemolytic anemias and uremia. Significant elevation of calcium levels were observed in all of these disorders except uremia. Nifedipine reduced or normalized the increased levels in most patients and its discontinuation resulted in a return of the abnormality. We propose that platelets in thromboses and related disorders are exposed to subcritical concentrations of activating factors, leading to enhanced calcium influx and elevated free cytoplasmic calcium followed by elevated resting dense tubular calcium. Nifedipine appears to protect platelets from these stimuli and coupled with their known action on vessel walls, calcium channel blockers show promise as antiatherogenic as well as antithrombotic agents.
AB - Using chlorotetracycline (CTC) as a probe we studied calcium homeostasis of platelets in various disorders. Studied were healthy subjects and patients with disorders where platelets play an important role. These included thromboses, hypertension, diabetes mellitus, vasculitis, immune thrombocytopenia, thrombotic thrombocytopenic purpura, myelofibrosis, hemolytic anemias and uremia. Significant elevation of calcium levels were observed in all of these disorders except uremia. Nifedipine reduced or normalized the increased levels in most patients and its discontinuation resulted in a return of the abnormality. We propose that platelets in thromboses and related disorders are exposed to subcritical concentrations of activating factors, leading to enhanced calcium influx and elevated free cytoplasmic calcium followed by elevated resting dense tubular calcium. Nifedipine appears to protect platelets from these stimuli and coupled with their known action on vessel walls, calcium channel blockers show promise as antiatherogenic as well as antithrombotic agents.
KW - artherosclerosis
KW - CTC probe
KW - platelet
KW - platelet calcium
KW - thromboses
UR - http://www.scopus.com/inward/record.url?scp=0023100122&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023100122&partnerID=8YFLogxK
U2 - 10.1016/0049-3848(87)90167-8
DO - 10.1016/0049-3848(87)90167-8
M3 - Article
C2 - 3563979
AN - SCOPUS:0023100122
VL - 45
SP - 135
EP - 143
JO - Thrombosis Research
JF - Thrombosis Research
SN - 0049-3848
IS - 2
ER -